Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chiappori

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|September 10, 2009
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive markerP N Munster, D Marchion, S Thomas, et al.
Oncotarget|November 29, 2017
A Bayesian pick-the-winner design in a randomized phase II clinical trialDung-Tsa Chen, Po-Yu Huang, Hui-Yi Lin, et al.
JTO Clinical and Research Reports|October 10, 2024
Unveiling the Molecular Features of SCLC With a Clinical RNA Expression PanelHilal Ozakinci, Aileen Y Alontaga, Pedro Cano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancerAlberto A Chiappori, Peter M Ellis, John Turner Hamm, et al.
Cancer|January 29, 2010
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumorsFaye M Johnson, Shruti Agrawal, Howard Burris, et al.
Cancer|October 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancerHirva Mamdani, Ryan D Gentzler, Lin Gu, et al.
Plos One|July 1, 2021
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancerDung-Tsa Chen, Wenyaw Chan, Zachary J Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
British Journal of Cancer|February 16, 2012
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerA A Chiappori, M T Schreeder, M M Moezi, et al.
Journal of Endocrinological Investigation|February 28, 2009
Prevalence of post-partum thyroiditis in Liguria (Italy): an observational studyU Filippi, R Brizzolara, D Venuti, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|September 10, 2009
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive markerP N Munster, D Marchion, S Thomas, et al.
Oncotarget|November 29, 2017
A Bayesian pick-the-winner design in a randomized phase II clinical trialDung-Tsa Chen, Po-Yu Huang, Hui-Yi Lin, et al.
JTO Clinical and Research Reports|October 10, 2024
Unveiling the Molecular Features of SCLC With a Clinical RNA Expression PanelHilal Ozakinci, Aileen Y Alontaga, Pedro Cano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancerAlberto A Chiappori, Peter M Ellis, John Turner Hamm, et al.
Cancer|January 29, 2010
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumorsFaye M Johnson, Shruti Agrawal, Howard Burris, et al.
Cancer|October 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancerHirva Mamdani, Ryan D Gentzler, Lin Gu, et al.
Plos One|July 1, 2021
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancerDung-Tsa Chen, Wenyaw Chan, Zachary J Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
British Journal of Cancer|February 16, 2012
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerA A Chiappori, M T Schreeder, M M Moezi, et al.
Journal of Endocrinological Investigation|February 28, 2009
Prevalence of post-partum thyroiditis in Liguria (Italy): an observational studyU Filippi, R Brizzolara, D Venuti, et al.
Pageof 6